Company Description
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoc...
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.
Valuation
Price to Book Ratio
1.44
Enterprise Value to EBITDA
1.22
Efficiency
Liquidity
Current Ratio
9.94
Quick Ratio
9.94
Cash Ratio
9.53
Profitability
Return on Assets
-61.50
Return on Equity
-68.48
Return on Total Capital
-66.25
Capital Structure
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. David Hering | 46 | 2021 | Chief Operating Officer |
Ms. Jane Pritchett V. Henderson | 57 | 2020 | Chief Financial Officer |
Dr. Laura Walker | 36 | 2020 | Chief Scientific Officer |
Dr. Rebecca L. Dabora | 62 | 2020 | Chief Technology & Manufacturing Officer |
Dr. Elham Hershberger | 53 | 2020 | Chief Development Officer |
Insider Actions
03/03/2022 |
Adimab LLC |
1,158,089 | 0 | |
08/10/2021 |
Adimab LLC |
25,860,700 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Mithril Capital Management LLC |
9,244,580 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Polaris Growth Management LLC |
320,160 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Polaris Growth Management LLC |
4,755,460 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Polaris Growth Management LLC |
28,520 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Polaris Growth Management LLC |
19,540 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Polaris Growth Management LLC |
55,595 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Polaris Growth Management LLC |
2,852,425 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Redmile Group LLC |
1,920,960 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Mithril Capital Management LLC |
1,997,000 | Acquisition at $17 per share. | 33,949,000 |
08/10/2021 |
Polaris Growth Management LLC |
177,500 | Acquisition at $17 per share. | 3,017,500 |
08/10/2021 |
Polaris Growth Management LLC |
45,000 | Acquisition at $17 per share. | 765,000 |
08/10/2021 |
Polaris Growth Management LLC |
2,678 | Acquisition at $17 per share. | 45,526 |
08/10/2021 |
Polaris Growth Management LLC |
1,834 | Acquisition at $17 per share. | 31,178 |
08/10/2021 |
Polaris Growth Management LLC |
5,219 | Acquisition at $17 per share. | 88,723 |
08/10/2021 |
Polaris Growth Management LLC |
267,769 | Acquisition at $17 per share. | 4,552,073 |
08/10/2021 |
Redmile Group LLC |
1,470,000 | Acquisition at $17 per share. | 24,990,000 |
MarketWatch News on ADGI
-
Biotech Stocks Are Still Falling. The Near-Term Outlook Is Grim.
- Barron's Online
-
Adagio Stock Spikes on New Data, but Its Omicron Problems Remain
- Barron's Online
-
Adagio Therapeutics downgraded to underweight at Morgan Stanley
- Tomi Kilgore
-
Adagio Therapeutics downgraded to hold from buy at Stifel, price target slashed to $9 from $50
- Tonya Garcia
-
Regeneron Says Covid-19 Treatment Might Not Work as Well Against Omicron
- Barron's Online
-
Adagio Therapeutics upgraded to overweight at Morgan Stanley
- Tomi Kilgore
-
Adagio Therapeutics started at buy with $57 stock price target at Stifel Nicolaus
- Tomi Kilgore
-
The IPO Market Is on Break. Adagio Is Friday's Only Deal.
- Barron's Online
-
Adagio Therapeutics sets IPO terms, to be valued at up to $1.8 bln
- Tomi Kilgore
Other News on ADGI
-
10-Q: ADAGIO THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
10-K: ADAGIO THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
AKBA, TMC and ISIG among mid-day movers
- Seeking Alpha
-
Why Adagio Therapeutics Stock Is Soaring Today
- Motley Fool
-
ABVC, SNOA and TISI among pre market gainers
- Seeking Alpha
-
2 Net Current Asset Value Stocks to Consider
- GuruFocus.com
-
- Seeking Alpha
-
Adagio Therapeutics names David Hering as interim CEO
- Seeking Alpha
-
Adagio falls after announcing resignation of CEO
- Seeking Alpha
-
GLSI, VCNX and ACY among mid-day movers
- Seeking Alpha
- Loading more headlines...